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Abstract 42 
Oral glucocorticoids (GC) preserve muscle strength and prolong walking in boys with Duchenne 43 
muscular dystrophy (DMD). Although vertebral fractures have been reported in boys taking GC, 44 
fracture rates for different GC regimes have not been investigated. The aim of this pragmatic 45 
longitudinal study was to compare growth, body mass, bone mineral density (BMD), vertebral 46 
fractures (VF) and ambulatory status in boys with DMD on daily (DAILY) or intermittent 47 
(INTERMITTENT), oral GC regimens. 48 
A convenience sample of 50 DMD boys from two centres was included in the study; 25 boys each 49 
were on the DAILY or INTERMITTENT regimen. Size adjusted lumbar spine BMD (LS BMAD), total 50 
body less head BMD (TBLH), by DXA and distal forearm bone densities by pQCT, GC exposure, VF 51 
assessment and ambulatory status were analysed at three time points; baseline, 1 and 2 years.  52 
At baseline, there were no differences in age, GC duration or any bone parameters. However, DAILY 53 
boys were shorter (height SDS DAILY= -1.4(0.9); INTERMITTENT= -0.8(1.0), p=0.04) with higher BMI 54 
(BMI SDS DAILY= 1.5(0.9); INTERMITTENT= 0.8(1.0), p=0.01). Over 2 years, DAILY boys got 55 
progressively shorter (delta height SDS DAILY= -0.9(1.1); INTERMITTENT= +0.1(0.6), p<0.001). At 56 
their 2 year assessment, 5 DAILY and 10 INTERMITTENT boys were non-ambulant. DAILY boys had 57 
more VFs than INTERMITTENT boys (10 versus 2; χ2 p = 0.008). BMAD SDS remained unchanged 58 
between groups. TBLH and radius BMD declined significantly but the rate of loss was not different.  59 
In conclusion, there was a trend for more boys on daily GCs to remain ambulant but at the cost of 60 
more VFs, greater adiposity and markedly diminished growth. In contrast, boys on intermittent GCs 61 
had fewer vertebral fractures but there was a trend for more boys to loose independent ambulation. 62 
Key words: Glucocorticoids, Muscular dystrophy, vertebral fracture, ambulation, bone density, 63 
growth 64 
 65 
  66 
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1. Introduction 67 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder, which affects 1 in 3600–68 
6000 live male births [1]. DMD is caused by loss of function mutations in the dystrophin gene, which 69 
encodes the dystrophin protein in muscle. Dystrophin deficiency results in necrosis of myofibres, 70 
which in turn results in progressive deterioration of muscle function. The disease manifests usually 71 
before 3 years of age with proximal muscle weakness and the inability to run and jump as their peers. 72 
As the disease progresses, rising from the floor becomes difficult and eventually independent 73 
ambulation is lost.  74 
Currently there is no cure for DMD but the quality of life of patients can be improved by medical 75 
treatment and supportive care. Long term treatment with oral glucocorticoids (GCs) slows down 76 
deterioration of skeletal muscle function, prolonging ambulation by 2 to 5 years [2]. Moderate quality 77 
evidence from RCTs demonstrates that GC treatment improves muscle function for about 12 months, 78 
and muscle strength for up to two years [3]. Treatment with GCs along with improved 79 
cardiorespiratory and orthopaedic supportive care, have led to improved survival of males with DMD. 80 
The current standard of care is to treat with prednisolone 0.75 mg/kg/day or deflazacort 0.9mg/kg/day; 81 
this treatment is initiated at the plateau of motor abilities between 4 and 6 years [1]. After loss of 82 
ambulation, steroid treatment may be continued, usually without further weight-related dose increase, 83 
or discontinued if side-effect burden is intolerable. Within the UK, GC treatment is given either daily or 84 
intermittently (10 days on & 10 days off) [4].  85 
Long-term GC treatment in DMD boys is associated with obesity, short stature, pubertal delay, and an 86 
increased risk of long bone and vertebral fractures (VFs) [5]. Fractures are associated with low bone 87 
mineral density (BMD) [6-12] and mainly caused by progressive muscle weakness and GC use[13]. 88 
Furthermore, GC-related growth deceleration and pubertal delay might also contribute to bone fragility 89 
in DMD boys [5]. Long bone fractures may precipitate permanent loss of mobility [8]. VFs may be 90 
asymptomatic or associated with severe localised back pain. The role of chronic GC therapy in the 91 
causation of VFs in DMD is emphasized by their absence in boys who are GC naïve [10]. Although 92 
VF have previously been reported in DMD boys taking GCs [7, 9-12, 14], fracture rate for different GC 93 
regimes has not been investigated.  94 
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Clinical observation suggests that DMD boys on continuous GC regimes may be more prone to VFs 95 
compared to those on intermittent regimes. However, to the best of our knowledge bone health 96 
outcomes have not been compared in DMD boys on different GC regimes. Thus, the aim of this study 97 
was to compare longitudinal growth, body mass, BMD, VFs and ambulatory status in boys with DMD 98 
on daily or intermittent, oral GC regimens. 99 
 100 
2. Materials and Methods 101 
This was a pragmatic study to compare the two different GC regimes. The majority of children 102 
from Manchester are treated using the continuous GC regime (DAILY), whilst the majority of children 103 
from Birmingham are treated using the intermittent 10 days on-10 days off regime (INTERMITTENT). 104 
The decision to commence GC therapy was made by the local neuromuscular consultant according to 105 
the guidelines used by the NorthStar network [4].  106 
2.1. Subjects 107 
A retrospective convenience sample of boys with established DMD was included, managed in two UK 108 
centres between 2006 and 2014. At both centres, boys were excluded if they were not on the daily or 109 
intermittent GC regime, for e.g. alternate day or weekend only regimes. Additionally, boys were 110 
excluded if they had had exposure to oral or intravenous bisphosphonate treatment at baseline bone 111 
assessment. At Manchester Children’s Hospital, 25 boys were selected who had undergone annual 112 
“bone health” assessments on at least 3 consecutive time points irrespective of their age (i.e. had at 113 
least 2 years follow up). The same number of children was then identified from Birmingham Children’s 114 
Hospital DMD bone database in order to match as far as possible with those in Manchester, by age 115 
and imaging modality. At both centres, bisphosphonate treatments were initiated when there was 116 
evidence of a VF and associated pain. This information was extracted from the boys’ medical records. 117 
At both centres, boys are routinely given advice to optimise their dietary calcium intake, preferably 118 
from low fat dairy products; they also receive vitamin D supplements and 25-hydroxy vitamin D levels 119 
are monitored annually.  120 
2.2. Ethics 121 
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Since this project was undertaken as a service / therapy evaluation between two UK centres, it did not 122 
require ethical approval [15]. 123 
2.3. Cumulative Glucocorticoid Exposure 124 
Cumulative GC exposure was calculated using information recorded in the subjects’ medical records.  125 
2.4. Anthropometric measurements 126 
Height and weight were measured and body mass index calculated as weight/height
2 
(kg/m
2
).  Once 127 
the child was unable to stand, arm span or supine length were used as surrogates for height. Height, 128 
weight and BMI measurements were transformed to standard deviation scores using the 1990 British 129 
growth reference data [16]. At both centres, anthropometric and bone assessments were repeated 130 
approximately annually.   131 
2.5. Ambulation Status 132 
At each bone imaging time-point, the subject’s mobility status was recorded, categorised as 133 
independently ambulant or requiring wheelchair assistance. 134 
2.6. Bone Health Assessments 135 
 136 
2.6.1.  Vertebral Fracture Assessment (VFA) 137 
 138 
The VFA was undertaken, at each measurement point, using all available spine imaging (e.g. CT 139 
scout views, anterior and lateral whole spine radiographs and Dual-Energy X-ray Absorptiometry 140 
(DXA).  Until recently vertebral fracture assessment, (VFA) by DXA was considered inferior to plain X‐141 
rays for the diagnosis of vertebral fracture. However, with the development of new higher‐resolution 142 
scanners, VFA by DXA is proving to be an attractive imaging tool for children. Compared to lateral 143 
radiographs, it affords the child a significant (approximately threefold) reduction in radiation dose and 144 
is available at the time of routine DXA scanning [17, 18]. 145 
Images from both centres were jointly reviewed by 2 experienced investigators (JEA & NJC) to arrive 146 
at a consensus on fracture identification. Fractures were defined if there was ≥ 25% loss in height of 147 
anterior, mid or posterior vertebral body, in relation to the adjacent unaffected vertebrae [19]. This 148 
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threshold was based on a UK based survey which suggested that ≥ 25% loss in vertebral height was 149 
the most likely level to prompt bisphosphonate treatment [20].  In addition, the identification of VFs 150 
with less than 25% vertebral height loss is unreliable both by plain radiography and DXA based VFA 151 
[17, 18].  152 
2.6.2. Long bone Fractures 153 
Data on long bone fractures was collected from review of hospital records and confirmed where 154 
possible from radiological review. 155 
2.6.3. Dual-Energy X-ray Absorptiometry (DXA) 156 
DXA scans of the lumbar spine (L1-4) and total body were performed on either a GE Lunar iDXA™ or 157 
Prodigy (GE Lunar Corp. Madison, WI, USA) (Birmingham) or a Hologic Discovery (QDR 4500 158 
Discovery, Hologic Inc. Bedford, MA) (Manchester) scanner, according to standard protocol. Results 159 
are presented as lumbar spine bone mineral apparent density [L1-L4 BMAD (g/cm
3
)] [21] and total 160 
body less head BMD [TBLH BMD (g/cm
2
)]. Age, gender and machine specific Z-scores were 161 
calculated using UK reference data [22]. 162 
2.6.4. Peripheral quantitative computed tomography (pQCT) 163 
At both sites, pQCT scans were acquired at the distal radius (4% of radial length) of the non-dominant 164 
forearm using a Stratec XCT-2000 scanner (Stratec, Pforzheim, Germany). Outcome variables 165 
included trabecular and total volumetric BMD (g/cm
3
). Age- and gender-specific Z-scores were 166 
calculated using the manufacturer’s reference data [23]. 167 
2.7. Statistical Analysis 168 
Analyses were performed using IBM SPSS Statistics version 22.0 (IBM Corp, Armonk, NY). 169 
Parameter differences from baseline to follow-up were evaluated using General Linear Model 170 
Repeated Measures analyses, with time as the within-subject factor and GC regime (DAILY or 171 
INTERMITTENT) as the between-subjects factor. If the sphericity assumption was not met, the 172 
Huynh-Feldt correction was applied. A level of p<0.05 was used to denote statistical significance. 173 
Results are presented as mean and standard deviation unless otherwise stated. 174 
 175 
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 176 
3. Results 177 
3.1. Baseline Characteristics 178 
By design, subjects from both GC regimes did not differ in age (mean (SD) 8.3 (2.4), age of GC 179 
therapy initiation (6.3 (1.9) years) or duration of GCs 2.0 (1.9) years). However, boys on the DAILY 180 
regime had greater cumulative GC exposure and were significantly shorter (height SDS -1.4 (1.0) vs. -181 
0.8 (1.0) p=0.04) with greater BMI (BMI SDS 1.5 (0.9) vs. 0.8 (1.0) p=0.01). In contrast, there were no 182 
differences in any of the measured bone density parameters between treatment regimens whether we 183 
included or excluded (data not shown) boys who subsequently went on to receive bisphosphonate 184 
therapy (Table 1).  One boy from the DAILY group and 3 boys from the INTERMITTENT group had 185 
suffered a long bone fracture.  In contrast, 1 of the DAILY boys had radiological evidence of a 186 
vertebral fracture, whereas none of the INTERMITTENT boys had evidence of vertebral fracture.  187 
3.2. Follow-up Data 188 
3.2.1. Growth and body mass 189 
After 2.5 (0.9) years, height SDS decreased significantly in the DAILY boys but remained constant for 190 
the INTERMITTENT boys (delta height SDS -0.9 (1.1) vs. +0.1 (0.6); p<0.001).  Weight SDS 191 
increased significantly in both the DAILY boys and INTERMITTENT boys (delta weight SDS +0.3 (0.8) 192 
vs. +0.7 (0.7); p=0.05). In contrast, BMI SDS increased at the same rate for both DAILY and 193 
INTERMITTENT boys (mean delta BMI SDS = +0.8 (0.8)). Consequently, BMI SDS for DAILY boys 194 
remained significantly higher at the final assessment (BMI SDS DAILY = +2.3 (0.7) vs. 195 
INTERMITTENT = +1.5 (1.0); p=0.001).  196 
3.2.2. Ambulation, fractures and bone density 197 
There was a non-significant trend for more boys in the INTERMITTENT regime to be non-ambulant. 198 
At their final assessment, mean age 10.7 (2.7) years, 10 boys on the INTERMITTENT regime (40%) 199 
and 5 in the DAILY group (20%) were non ambulant (Figure 1a). 200 
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During follow-up, one DAILY boy sustained a minimally displaced metaphyseal fracture of the distal 201 
tibia. None of the INTERMITTENT boys sustained any long bone fractures. Over the same period, 10 202 
(40%) DAILY and 2 (8%) INTERMITTENT boys suffered VFs (χ
2 
=7.018; p =0.008) (Figure1b). Six of 203 
the 10 DAILY boys with symptomatic VF prior to the 2 year assessment were commenced on 204 
intravenous bisphosphonate therapy. As such, bone density data from these 6 boys were excluded 205 
from follow-up comparisons.  206 
LS BMAD Z-scores did not change over time and did not differ between the treatment groups. In 207 
contrast, Z-scores for TBLH BMD, TotBMD and TrabBMD at the 4% distal radial site decreased 208 
significantly (p<0.05) with time. However, there was no statistical interaction between GC regime and 209 
time for any of the bone parameters (Table 2). 210 
Similar differences were observed combining GC regimes and grouping according to fracture. There 211 
were no significant differences in LS BMAD or TBLH BMD Z-scores between those that did or did not 212 
suffer a VF. However, TotBMD and TrabBMD Z-scores at the 4% distal radius were significantly lower 213 
in boys who fractured (p<0.05), and declined (p<0.05) over time in both groups (Table 3 & Figure 2b).  214 
 215 
4. Discussion 216 
This study found that boys on the DAILY GC regime suffered significantly more VFs than those on the 217 
INTERMITTENT GC regimen but more tended to be ambulant at the end of the observation period. 218 
DAILY boys were also shorter, grew less and had greater BMI.   219 
Despite the striking differences in VFs there were no differences in BMAD between DAILY and 220 
INTERMITTENT  GC regimes either at baseline or over the duration of follow-up. Similarly, in the 221 
whole group, there were also no differences in BMAD between boys with VFs and those without. Thus 222 
BMAD, in DMD boys treated with GC, does not appear to be a predictive marker of vertebral fracture.  223 
This supports observations in children with nephrotic syndrome [24] but contrasts findings from the 224 
STOPP study in children with acute lymphoblastic leukaemia, nephrotic syndrome and rheumatoid 225 
arthritis, where low areal BMD was a significant predictor of VFs [25, 26].  The lumbar spine BMAD 226 
may not be useful for differentiating boys with and without VFs in DMD.  227 
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Distal radial total and trabecular bone density measured by pQCT were not different between GC 228 
regimes at baseline. However, in contrast to BMAD, the pQCT density (g/cm
3
) Z-scores decreased 229 
over time. We postulate that the differences between BMAD and pQCT distal radial densities may be 230 
due to the higher amount of trabecular bone in the pQCT measured distal radial parameters and the 231 
greater sensitivity of pQCT to detect trabecular changes. Adult studies indicate that GC have a 232 
predilection to affect the more metabolically active trabecular bone [27]. If this holds true for children, 233 
it would explain why reductions in trabecular rich sites as measured by pQCT are more sensitive to 234 
change than the lumbar spine.  235 
It is generally assumed that BMAD reflects predominantly trabecular bone density of the spine; 236 
however, because DXA measures the whole projection, at the lumbar spine it invariably includes the 237 
cortical spinous processes. The combination of trabecular bone in the vertebral body with the cortical 238 
bone from the spinous processes may mask any changes within the trabecular compartment arising 239 
from GC and progressive immobility of the DMD boys. Although DXA remains the preferred method of 240 
bone health assessment in children [28], it is well known that areal bone mineral density, as 241 
measured by DXA, is significantly affected by bone size. Children with reduced stature and hence 242 
reduced bone size will have spuriously low areal bone mineral density [29].  In our group of boys the 243 
mean Z score for height, in both groups at the start of the assessment was reduced. However, boys 244 
on the DAILY regime were already significantly shorter at baseline and grew less than the intermittent 245 
group. To overcome the known pitfall of bone size in DXA imaging, we used the bone mineral 246 
apparent density (BMAD) to assess their bone changes [28]. However, even though BMAD reduces 247 
the size influence it is only an approximation for true volumetric bone density. As such, quantitative 248 
computed tomography (QCT) of the lumbar spine may be a more appropriate lumbar spine bone 249 
density technique to apply in children with DMD. We speculate that volumetric BMD by spine QCT 250 
may a better predictor of vertebral fracture. Longitudinal studies are needed to answer this question 251 
[30]. 252 
Our pragmatic study has a number of shortcomings. The data on ambulatory status was gathered 253 
from review of patient’s records. Since patients were reviewed in at roughly 6 monthly intervals at 254 
both centres accurate documentation of exact time of loss of ambulation was not always possible and 255 
would often rely on parent recalling this information. Again the information on GC dose was estimated 256 
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from patient records. There were some differences in the annual bone heath assessments. Most 257 
notably bone density measures were acquired on different bone densitometers. However, the 258 
machine differences were minimised by using Z-scores from a robust reference dataset [22]. There 259 
were also differences in the imaging type from which vertebral fractures were assessed annually but 260 
again these differences were minimised by reviewing the images and consensus reporting by 2 261 
investigators experienced in vertebral morphometry (JEA & NJC). It is feasible that the assessment of 262 
bone density may be affected by differences in adiposity. Experimental work with phantoms has 263 
shown that increasing adiposity increases the detected bone area and consequently results in 264 
artificially lower bone density values [31]. However, these measurement errors have not been 265 
quantified in children and as such it is difficult to assess the true impact they have on our different 266 
treatment groups with statistically different levels of adiposity.  Consequently, further work on the 267 
relationship between lumbar spine BMAD and vertebral fracture is required as this study was not 268 
powered to statistically evaluate changes in bone density. 269 
5. Conclusion 270 
In summary, boys on a daily GC regimen tend to remain ambulant longer but at the cost of 271 
significantly more VFs, greater adiposity and markedly diminished growth. In contrast, boys on the 272 
intermittent GC regimen had fewer fractures but tended to lose ambulation earlier. In both groups, LS 273 
BMAD was a poor predictor of VFs. The high prevalence of VF, and the limited value of DXA to 274 
predict VF, suggests the need for VF screening as part of the boys routine bone health assessments. 275 
Finally, the decline in volumetric bone density as measured by peripheral QCT may be a more 276 
sensitive measure of bone loss and vertebral fracture risk.  277 
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Table 1 Baseline characteristics of the DMD boys in each GC regimen (Mean (SD)) 407 
 
DAILY Steroid 
Regime 
(n = 25)  
INTERMITTENT 
Steroid Regime 
(n = 25) 
Difference 
p value 
Age (years) 
8.1  
(2.3)  
8.5 
(2.7) 
NS 
Height SDS 
-1.4 
(0.9) 
-0.8 
(1.0) 
0.04 
Weight SDS 
0.3 
(0.9) 
0.1 
(1.1) 
NS 
BMI SDS 
1.5 
(0.9) 
0.8 
(1.0) 
0.01 
Age started glucocorticoids 
6.0 
(1.9) 
6.5 
(1.8) 
NS 
Duration of Steroids (years) 
2.1  
(1.6) 
2.0 
(2.2) 
NS 
Cumulative glucocorticoid dose (mg) 
11278 
(7248) 
6397 
(7543) 
0.02 
Lumbar Spine BMAD (g/cm
3
) 
Z-Score 
-0.6 
(0.7) 
-0.3 
(1.0) 
NS 
Total Body Less Head BMD (g/cm
2
) 
Z-Score 
-2.3 
(1.2) 
-1.8 
(0.8) 
NS 
4% Distal Radius Total Density (g/cm
3
) 
Z-Score 
-0.5 
(1.5) 
-0.8 
(1.2) 
NS 
4% Distal Radius Trabecular Density (g/cm
3
) 
Z-Score 
-1.1 
(1.5) 
-1.3 
(1.2) 
NS 
Number of boys with long bone fractures 1 3  
Number of boys with vertebral fractures 1 0  
 408 
Note: 409 
Abbreviation: BMAD Bone Mineral Apparent Density 410 
  411 
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Table 2 Mean (SD) Bone density Z-scores of DMD boys on DAILY and INTERMITTENT steroid 412 
regimen (excluding 6 boys who started bisphosphonate treatment due to symptomatic vertebral 413 
fractures) 414 
 415 
 DAILY Steroid Regime INTERMITTENT  Steroid Regime 
Z-Scores Baseline 
n = 19 
Year 1 
n = 19 
Year 2 
n = 19 
Baseline 
n = 25 
Year 1 
n = 25 
Year 2 
n = 25 
Lumbar Spine 
BMAD  
-0.6 
(0.7) 
-0.6 
(0.7) 
-0.4 
(0.9) 
-0.3 
(1.0) 
-0.1 
(1.0) 
-0.1 
(1.1) 
*Total Body Less 
Head BMD 
-2.3 
(1.2) 
-2.4 
(1.5) 
-3.1 
(1.3) 
-1.8 
(0.8) 
-1.9 
(0.9) 
-2.0 
(0.9) 
*4% Distal Radius 
Total Density  
-0.2 
(1.3) 
-1.0 
(1.4) 
-1.0 
(1.4) 
-0.8 
(1.2) 
-1.2 
(1.0) 
-1.4 
(1.2) 
*4% Distal Radius 
Trabecular Density 
-0.9 
(1.4) 
-1.2 
(1.0) 
-1.9 
(1.3) 
-1.3 
(1.2) 
-1.5 
(1.1) 
-1.8 
(1.2) 
Note: 416 
Abbreviation: BMAD Bone Mineral Apparent Density 417 
* Significant change over time (p<0.05) but no significant interaction between GC regime and bone 418 
density over time. 419 
 420 
 421 
  422 
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Table 3 Mean (SD) Bone density Z-scores of boys with and without vertebral fractures at the end of 423 
the study (excluding 6 boys who started bisphosphonate treatment due to symptomatic vertebral 424 
fractures) 425 
 426 
 No Vertebral Fractures Vertebral Fractures 
Z-Scores Baseline 
(n = 38) 
Year 1 
(n = 38) 
Year 2 
(n = 38) 
Baseline 
(n = 6) 
Year 1 
(n = 6) 
Year 2 
(n = 6) 
Lumbar Spine BMAD  -0.4 
(0.8) 
-0.3 
(0.8) 
-0.2 
(0.9) 
-0.4 
(1.4) 
-0.6 
(1.4) 
-0.7 
(1.6) 
Total Body Less Head 
BMD 
-1.8 
(0.9) 
-2.0 
(1.1) 
-2.3 
(1.2) 
-2.7 
(1.0) 
-2.7 
(0.9) 
-3.2 
(1.1) 
*4% Distal Radius 
Total Density  
-0.5 
(1.3) 
-0.9 
(0.7) 
-1.1 
(1.3) 
-1.2 
(0.7) 
-2.2 
(0.7) 
-2.3 
(0.6) 
*4% Distal Radius 
Trabecular Density 
-1.0 
(1.2) 
-1.3 
(1.1) 
-1.7 
(1.2) 
-2.1 
(1.2) 
-2.0 
(0.8) 
-2.6 
(1.3) 
Note: 427 
Abbreviation: BMAD Bone Mineral Apparent Density 428 
*Significantly different at baseline and significant change over time (p<0.05) but no significant 429 
interaction between fracture and bone density over time. 430 
 431 
 432 
 433 
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Figure Legends 435 
 436 
Figure 1  Changes in ambulation over time (a). There was a trend for more boys on the DAILY 437 
GC regime (20%) (Black boxes) to remain ambulant after two years than boys on the INTERMITTENT 438 
(40%) (Grey boxes). Occurrences of vertebral fracture (b). Significantly more vertebral fractures were 439 
reported in boys on the DAILY regime (40%) (Black boxes) than the INTERMITTENT regime (8%) 440 
(Grey boxes) (χ
2
; p = 0.008). 441 
 442 
Figure 2  Bone density differences between the vertebral fracture group (n= 6, black circles) 443 
and non-vertebral fracture group (n= 38 grey squares). (a) Demonstrates no significant difference in 444 
LSBMAD Z-scores between groups (n= 38). In contrast, (b) demonstrates the reduction in baseline 445 
TotBMD Z-scores at the 4% distal radius for DMD boys who suffered a vertebral fracture and their 446 
greater drop in TotBMD Z-scores over time, as measured by pQCT.  447 
 448 
